Dr. Charles Langelier is a physician-scientist whose work operates at the intersection of infectious diseases, critical care medicine, genomics, and public health. His laboratory leverages multiomic technologies to deepen the understanding and improve the management of pneumonia, sepsis, and other infectious/inflammatory syndromes. Dr. Langelier’s research encompasses three central areas: developing novel molecular diagnostics for infectious diseases, studying the host/pathogen biology of pneumonia and sepsis, and advancing methods for the surveillance of emerging infections. 

Significant contributions include pioneering the development of culture-independent pneumonia and sepsis diagnostics that integrate host gene expression profiling, unbiased pathogen detection and profiling of the microbiome. He has utilized this approach to explore the biological interactions between hosts and microbes in pneumonia, COVID-19, sepsis, and ARDS. In this realm, his work has included investigating mechanisms of post-viral bacterial superinfection, identifying, and characterizing molecular subphenotypes of critical illness syndromes, and evaluating the impact of aging on host inflammatory responses. In addition, Dr. Langelier have leveraged microbial genomics to advance approaches for pandemic preparedness. This includes developing new methods for detecting and tracking antimicrobial resistant microbes, and demonstrating culture-independent metagenomics as a tool for the surveillance of emerging pneumonia and sepsis pathogens. 

Beyond his research, Dr. Langelier is committed to guiding and teaching of the next generation of medical professionals and scientists. His laboratory strives to create an inclusive environment with trainees and professional scientists from a diversity of backgrounds and geographic upbringings. Together, by combining research, clinical practice, and mentoring, Dr. Langelier aims to advance the management and comprehension of critical and emerging infectious diseases while uplifting the next generation of clinical investigators.